News Urinary Tract Symptoms Found to Affect 70% of MS Patients in Study and Contribute to Disability Urinary Tract Symptoms Found to Affect 70% of MS Patients in Study and Contribute to Disability by Patricia Silva, PhD | April 13, 2016 Share this article: Share article via email Copy article link Urinary tract symptoms affect a large proportion of patients with multiple sclerosis (MS), yet their extent and type is not well-known. A study reported that among a cohort of people with the disease, almost 70 percent had urinary tract problems, adding to the extent of their disability. The study, “Clinical Characteristics and Urodynamic Analysis of Urinary Dysfunction in Multiple Sclerosis,“Ā was published in the Chinese Medical Journal. Researchers atĀ Capital Medical UniversityĀ inĀ Beijing enrolled 126 MS patients ā a group composed of 30 peopleĀ with clinically isolated syndrome (CIS), 64 with relapsing-remitting MS (RRMS), 10 with primary progressive MS (PPMS), and 22 with secondary progressive MS (SPMS). In this sample, 67.5 percent had lower urinary tract symptoms, most frequently in the form of urgency to urinate. The most common urological abnormality was an overactive bladder muscle, likely the main cause of feelings of urgency asĀ 71.6 percent of patients with urgency also had an overactive bladder. Other common symptoms were frequent urination, urge incontinence, and stress incontinence. Urological symptoms wereĀ associated with more severe disability, as assessed by the expanded disability status scale (EDSS). Particularly, a scale measuring the severity of overactive bladder indicated that the greater theĀ bladder symptoms, the higher the disability. CIS patients had fewer instances ofĀ overactive bladder and less disability than RRMS or progressive MS patients, but the research team could not observe any difference between theĀ RRMS and progressive MS groups. The researchers also explored if MS treatment impacted urinary tract symptoms, and noted improvement in some parameters in all groups following treatment. The study, however, did not distinguish among different types of treatment, ranging from immunomodulatory therapiesĀ with interferon over methylprednisolone and behavioral therapy. The study also mentioned that urinary tract symptoms were treated with both anticholinergic drugs and intermittent catheterization. The mean treatment period was only 14 days, and each MS type showed improvements in different parameters. These factors make it difficult to draw any firm conclusions about MS treatment and potential improvement in urinary tract function. Nevertheless, measuring urinary tract function parameters might guide clinicians in their management decisions, and possibly offer prognostic clues of the risk for upper urinary tract deterioration. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags disability, overactive bladder
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk